CRISPR Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- CRISPR Therapeutics's estimated annual revenue is currently $58.9M per year.
- CRISPR Therapeutics received $113.8M in venture funding in January 2018.
- CRISPR Therapeutics's estimated revenue per employee is $155,000
- CRISPR Therapeutics's total funding is $218M.
- CRISPR Therapeutics has 380 Employees.
- CRISPR Therapeutics grew their employee count by 39% last year.
- CRISPR Therapeutics currently has 48 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is CRISPR Therapeutics?
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.keywords:N/A
Number of Employees
Employee Growth %
|Christopher Erdman||Vice President, Investor Relations & External Affairs||Email Available|
|Marc Becker||Chief Financial Officer||Email Available|
|Susan Kim||Vice President, Investor Relations||Email Available|
|Michael Bruce||Senior VP, Program Portfolio & Alliance Management||Email Available|
|Jonathan Jones||Vice President, New Business Opportunities||Email Available|
|Abhinav Shukla||Vice President And Head, Manufacturing|
|Himanshu Garg||Sr. Director, Enterprise Business Systems|
|James Kasinger||General Counsel|
|Matthias Will||Vp Clinical Development|
|Demetrios Kalaitzidis||Director, Immuno-Oncology|
CRISPR Therapeutics News
BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 ...
A trial helmed by Massachusetts-based Vertex Pharmaceuticals and CRISPR Therapeutics is the first CRISPR-based clinical trial in the U.S. for ...
CRISPR Therapeutics (NASDAQ:CRSP) inks an agreement with Jefferies for the at-the-market sale of up to $200M of its common stock.
CRISPR Therapeutics Funding
|2018-01-04||$115.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2018-01-08||$113.8M||Undisclosed||Goldman Sachs & Co. LLC||Article|
CRISPR Therapeutics Executive Hires